HRP20211628T1 - Frakcije krvne plazme kao tretman za kongitivne poremećaje povezane sa starenjem - Google Patents
Frakcije krvne plazme kao tretman za kongitivne poremećaje povezane sa starenjem Download PDFInfo
- Publication number
- HRP20211628T1 HRP20211628T1 HRP20211628TT HRP20211628T HRP20211628T1 HR P20211628 T1 HRP20211628 T1 HR P20211628T1 HR P20211628T T HRP20211628T T HR P20211628TT HR P20211628 T HRP20211628 T HR P20211628T HR P20211628 T1 HRP20211628 T1 HR P20211628T1
- Authority
- HR
- Croatia
- Prior art keywords
- ppf
- treatment
- use according
- plasma
- aging
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 title claims 3
- 230000002431 foraging effect Effects 0.000 title 1
- 210000002381 plasma Anatomy 0.000 title 1
- 108010058237 plasma protein fraction Proteins 0.000 claims 13
- 229940081857 plasma protein fraction Drugs 0.000 claims 13
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010017384 Blood Proteins Proteins 0.000 claims 1
- 102000004506 Blood Proteins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 108010074605 gamma-Globulins Proteins 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (6)
1. Proteinska frakcija plazme (PPF) za uporabu u liječenju kognitivnih poremećaja povezanih sa starenjem, pri čemu se učinkovita količina PPF-a daje subjektu s dijagnosticiranim kognitivnim poremećajem povezanim sa starenjem, pri čemu PPF ima ukupni sadržaj proteina koji se sastoji od najmanje 83%, ali manje od 95% albumina, ne više od 17% globulina i drugih proteina plazme, te ne više od 1% gama globulina, pri čemu je navedeni PPF izveden iz ljudske plazme.
2. PPF za uporabu u skladu sa zahtjevom 1, gdje je PPF komercijalno dostupan PPF.
3. PPF za uporabu u skladu s bilo kojim od prethodnih zahtjeva nadalje obuhvaća praćenje subjekta radi poboljšanja kognitivne funkcije.
4. PPF za uporabu u skladu s bilo kojim od prethodnih zahtjeva, naznačen time što se PPF dobiva iz plazme od skupine ljudi mlađih od 40 godina.
5. PPF za uporabu u skladu s bilo kojim od prethodnih zahtjeva, gdje je subjekt sisavac.
6. PPF za uporabu u skladu s patentnim zahtjevom 7, gdje je sisavac čovjek.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376529P | 2016-08-18 | 2016-08-18 | |
| US201662412258P | 2016-10-24 | 2016-10-24 | |
| PCT/US2017/029953 WO2018034712A1 (en) | 2016-08-18 | 2017-04-27 | Blood plasma fractions as a treatment for aging-associated cognitive disorders |
| EP17841780.4A EP3484502B1 (en) | 2016-08-18 | 2017-04-27 | Blood plasma fractions as a treatment for aging-associated cognitive disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211628T1 true HRP20211628T1 (hr) | 2022-02-04 |
Family
ID=61196950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211628TT HRP20211628T1 (hr) | 2016-08-18 | 2017-04-27 | Frakcije krvne plazme kao tretman za kongitivne poremećaje povezane sa starenjem |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20190321449A1 (hr) |
| EP (2) | EP3995140A1 (hr) |
| JP (3) | JP7316931B2 (hr) |
| KR (3) | KR20240036720A (hr) |
| CN (2) | CN115957309A (hr) |
| AU (3) | AU2017312722B2 (hr) |
| BR (1) | BR112019003172A2 (hr) |
| CA (1) | CA3033051A1 (hr) |
| CL (1) | CL2019000304A1 (hr) |
| CY (1) | CY1124695T1 (hr) |
| DK (1) | DK3484502T3 (hr) |
| ES (1) | ES2899147T3 (hr) |
| HR (1) | HRP20211628T1 (hr) |
| HU (1) | HUE056294T2 (hr) |
| IL (2) | IL264660B2 (hr) |
| LT (1) | LT3484502T (hr) |
| MA (1) | MA45692B1 (hr) |
| MD (1) | MD3484502T2 (hr) |
| MX (1) | MX2019001718A (hr) |
| NZ (1) | NZ750885A (hr) |
| PL (1) | PL3484502T3 (hr) |
| PT (1) | PT3484502T (hr) |
| RS (1) | RS62558B1 (hr) |
| SG (1) | SG11201901273TA (hr) |
| SI (1) | SI3484502T1 (hr) |
| UA (1) | UA126232C2 (hr) |
| WO (1) | WO2018034712A1 (hr) |
| ZA (1) | ZA202004834B (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4299129A3 (en) * | 2017-04-26 | 2024-03-20 | Alkahest, Inc. | Dosing regimen for treatment of cognitive impairments with blood plasma products |
| MX2020011114A (es) | 2018-05-15 | 2021-01-29 | Alkahest Inc | Tratamiento de enfermedades asociadas con el envejecimiento con moduladores de la leucotrieno a4 hidrolasa. |
| CN110724176B (zh) * | 2018-07-16 | 2021-10-26 | 北京豪思生物科技有限公司 | 一种治疗阿尔茨海默症的血浆蛋白分离物及其制备方法和应用 |
| CN110787187B (zh) * | 2018-07-16 | 2022-05-13 | 北京豪思生物科技股份有限公司 | 一种增强记忆力和提高认知功能的血浆混合物及其制备方法和应用 |
| WO2020018343A1 (en) * | 2018-07-20 | 2020-01-23 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| JP2022505915A (ja) | 2018-10-26 | 2022-01-14 | アルカヘスト，インコーポレイテッド | 疼痛、創傷治癒及び術後回復の改善のための血漿及び血漿画分の使用 |
| CN110448686B (zh) * | 2019-09-19 | 2022-11-04 | 北京豪思生物科技股份有限公司 | 铜蓝蛋白联合运铁蛋白的应用 |
| WO2021062007A1 (en) * | 2019-09-25 | 2021-04-01 | Cytegen Corp. | Treatment of mitochondrial deficits and age-related diseases using blood products |
| CA3151943A1 (en) | 2019-11-04 | 2021-05-14 | Viktoria Kheifets | Blood plasma fractions for use in muscle regeneration |
| US11484551B2 (en) | 2019-11-20 | 2022-11-01 | Alkahest, Inc. | Method of treating liver failure with plasma fraction IV-4 |
| CN114746100A (zh) | 2019-11-20 | 2022-07-12 | 万能溶剂有限公司 | 用于肝再生的血浆级分 |
| CA3221177A1 (en) | 2021-11-01 | 2023-05-04 | Meghan Kerrisk Campbell | Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3869431A (en) | 1973-03-12 | 1975-03-04 | Firestone Tire & Rubber Co | Polyamides and their production |
| US4624780A (en) | 1982-06-28 | 1986-11-25 | Alpha Therapeutic Corporation | Fractionation of blood plasma |
| DE3612137A1 (de) * | 1986-04-10 | 1987-10-15 | Biotest Pharma Gmbh | Steriles plasmaaustauschmittel |
| US5138034A (en) * | 1989-07-12 | 1992-08-11 | The Green Cross Corporation | Method of fractionating plasma proteins |
| US5110907A (en) | 1989-08-01 | 1992-05-05 | Alpha Therapeutic Corporation | Factor viii complex purification using heparin affinity chromatography |
| US5288853A (en) | 1992-04-30 | 1994-02-22 | Alpha Therapeutic Corporation | Factor viii purification process |
| US5219995A (en) | 1992-07-14 | 1993-06-15 | Alpha Therapeutic Corporation | Plasma fraction purification |
| US5561115A (en) * | 1994-08-10 | 1996-10-01 | Bayer Corporation | Low temperature albumin fractionation using sodium caprylate as a partitioning agent |
| US20050143310A1 (en) * | 2001-05-11 | 2005-06-30 | Masaki Hirashima | Novel remedies for neurodegenerative disease |
| US20070010435A1 (en) * | 2002-12-19 | 2007-01-11 | New York University | Method for treating amyloid disease |
| US20040146565A1 (en) * | 2003-01-28 | 2004-07-29 | Lauridsen Group Incorporated | First lipoprotein fraction and therapeutic compositions of same |
| US20130121979A1 (en) * | 2003-12-29 | 2013-05-16 | Allan Mishra | Method of treating cancer using platelet compositions |
| ES2257225B1 (es) | 2006-02-17 | 2007-03-16 | Grifols, S.A | Preparacion terapeutica de fviia de muy alta pureza y metodo para su obtencion. |
| ES2332846B1 (es) * | 2007-10-26 | 2010-07-08 | Grifols, S.A. | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos. |
| PT2271382E (pt) | 2008-04-15 | 2013-05-07 | Grifols Therapeutics Inc | Ultrafiltração em dois andares/diafiltração |
| US20090297485A1 (en) * | 2008-05-28 | 2009-12-03 | Allan Mishra | Compositions and methods for treating psychiatric and neurodegenerative disorders |
| AU2013203043B2 (en) * | 2013-03-15 | 2016-10-06 | Takeda Pharmaceutical Company Limited | Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs |
| WO2014182631A1 (en) * | 2013-05-06 | 2014-11-13 | Baxter International Inc. | Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g |
| CN106163530A (zh) * | 2013-12-09 | 2016-11-23 | 小利兰·斯坦福大学托管委员会 | 用于治疗衰老相关病症的方法和组合物 |
| ES2524516B1 (es) | 2014-05-29 | 2015-03-31 | Grifols Worldwide Operations Limited | Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido |
| EA039316B1 (ru) * | 2016-10-24 | 2022-01-12 | Алкахест, Инк. | Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением |
| US11040068B2 (en) * | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| EP4299129A3 (en) * | 2017-04-26 | 2024-03-20 | Alkahest, Inc. | Dosing regimen for treatment of cognitive impairments with blood plasma products |
-
2017
- 2017-04-27 HR HRP20211628TT patent/HRP20211628T1/hr unknown
- 2017-04-27 EP EP21192528.4A patent/EP3995140A1/en active Pending
- 2017-04-27 AU AU2017312722A patent/AU2017312722B2/en active Active
- 2017-04-27 ES ES17841780T patent/ES2899147T3/es active Active
- 2017-04-27 DK DK17841780.4T patent/DK3484502T3/da active
- 2017-04-27 WO PCT/US2017/029953 patent/WO2018034712A1/en unknown
- 2017-04-27 KR KR1020247007926A patent/KR20240036720A/ko active Search and Examination
- 2017-04-27 HU HUE17841780A patent/HUE056294T2/hu unknown
- 2017-04-27 KR KR1020227025297A patent/KR20220107322A/ko not_active IP Right Cessation
- 2017-04-27 MA MA45692A patent/MA45692B1/fr unknown
- 2017-04-27 BR BR112019003172A patent/BR112019003172A2/pt not_active Application Discontinuation
- 2017-04-27 CN CN202211658689.8A patent/CN115957309A/zh active Pending
- 2017-04-27 EP EP17841780.4A patent/EP3484502B1/en active Active
- 2017-04-27 SG SG11201901273TA patent/SG11201901273TA/en unknown
- 2017-04-27 PL PL17841780T patent/PL3484502T3/pl unknown
- 2017-04-27 CA CA3033051A patent/CA3033051A1/en active Pending
- 2017-04-27 CN CN201780057412.0A patent/CN109963582B/zh active Active
- 2017-04-27 JP JP2019508828A patent/JP7316931B2/ja active Active
- 2017-04-27 UA UAA201901438A patent/UA126232C2/uk unknown
- 2017-04-27 MX MX2019001718A patent/MX2019001718A/es unknown
- 2017-04-27 IL IL264660A patent/IL264660B2/en unknown
- 2017-04-27 SI SI201730964T patent/SI3484502T1/sl unknown
- 2017-04-27 KR KR1020197007543A patent/KR20190032614A/ko not_active IP Right Cessation
- 2017-04-27 IL IL304946A patent/IL304946A/en unknown
- 2017-04-27 NZ NZ750885A patent/NZ750885A/en unknown
- 2017-04-27 LT LTEPPCT/US2017/029953T patent/LT3484502T/lt unknown
- 2017-04-27 PT PT178417804T patent/PT3484502T/pt unknown
- 2017-04-27 RS RS20211337A patent/RS62558B1/sr unknown
- 2017-04-27 MD MDE20190622T patent/MD3484502T2/ro unknown
-
2019
- 2019-02-05 CL CL2019000304A patent/CL2019000304A1/es unknown
- 2019-06-28 US US16/456,717 patent/US20190321449A1/en not_active Abandoned
-
2020
- 2020-01-09 AU AU2020200181A patent/AU2020200181B2/en active Active
- 2020-07-16 ZA ZA2020/04834A patent/ZA202004834B/en unknown
-
2021
- 2021-09-28 AU AU2021240142A patent/AU2021240142A1/en active Pending
- 2021-11-05 CY CY20211100958T patent/CY1124695T1/el unknown
- 2021-12-15 JP JP2021203571A patent/JP7447069B2/ja active Active
-
2022
- 2022-01-24 US US17/582,974 patent/US20220152161A1/en active Pending
-
2023
- 2023-08-17 JP JP2023133021A patent/JP2023156459A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211628T1 (hr) | Frakcije krvne plazme kao tretman za kongitivne poremećaje povezane sa starenjem | |
| EA201990594A1 (ru) | Анти-tim-3 антитела и их применение | |
| EA201790377A1 (ru) | Антитела к глюкагону и их применения | |
| MX2015009416A (es) | Anticuerpos humanos de la proteina f del virus respiratorio sincitial y metodos de uso de estos. | |
| WO2016071376A3 (en) | Fc-region variants with modified fcrn-binding and methods of use | |
| MX2018009011A (es) | Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos. | |
| PH12016501391A1 (en) | High affinity and aggregatively stable antibodies on the basis of vairable domain vl and a derivative vhh | |
| EA202191133A1 (ru) | Сигнатуры интерферона типа i и способы их применения | |
| Corcoran et al. | Developmental trajectory of mismatch negativity and visual event-related potentials in healthy controls: Implications for neurodevelopmental vs. neurodegenerative models of schizophrenia | |
| MX2022010954A (es) | Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo. | |
| MA39912B1 (fr) | Dérivés de 2-aryl-4-hydroxy-1,3-thiazole comme antagonistes du trpm8, et leur utilisation dans le traitement de la neuralgie, de la douleur, de la bpco et de l'asthme. | |
| Shang et al. | Family social class and meaning in life: Mediating of basic psychological need satisfaction. | |
| MX2019006446A (es) | Métodos para inducir tolerancia inmunológica a factores de coagulación. | |
| MA47844A (fr) | Combinaison comprenant du palmitoyléthanolamide (pea) et du e lycopène pour utilisation dans le traitement de maladies inflammatoires | |
| Sandoz et al. | Building awareness, openness, and action: Values work in behavior therapy. | |
| RU2014113841A (ru) | Способ ранней диагностики эндогенной интоксикации | |
| Jean | Diagnosing and classifying anemia in adult primary care | |
| Gilak et al. | The relationship of resiliency and self-concept with self-efficacy of handicapped females: The mediating role of creativity. | |
| MA53138A (fr) | Dérivés de 3-(5-hydroxy-1-oxoisoindoline-2-yl)pipéridine-2,6-dione et leur utilisation dans le traitement de maladies dépendantes du doigt de zinc 2 de la famille ikaros (ikzf2) | |
| IT201700029316A1 (it) | Composizione per uso nel trattamento dell'endometriosi e dei sintomi associati all’endometriosi | |
| EA202090460A1 (ru) | Композиции и способы для лечения нейронального повреждения | |
| EA201991340A1 (ru) | Способы индуцирования иммунологической толерантности к факторам свертывания крови | |
| Praet et al. | Are 25 (OH) vitamin D and salivary-IgA risk factors for illness in Olympic athletes? | |
| Pirani | Paid work and well-being: findings for Italian temporary workers | |
| Ni et al. | Abusive supervision and academic procrastination in undergraduates: A multiple mediation model. |